Enveda secures $311M Series E funding to advance AI drug discovery

Enveda, a biotech startup focused on discovering nature-derived drugs using AI, has raised $311 million in a Series E funding round, achieving a valuation of $2 billion. The funding was led by Catalio Capital Management with participation from Iconiq and others, doubling the company's valuation from a year ago. Enveda is currently advancing several AI-discovered drug candidates into clinical trials.